J Breast Cancer.
2024 Dec;27(6):383-394. 10.4048/jbc.2024.0186.
Characteristics and Prognosis of Breast Cancer Patients With Prior Hormone Replacement Therapy: Insights From the Korean Breast Cancer Society Registry
- Kim CW
1 - Jung Y2
- Jeong J3
- Kim HJ4
- Choi JE5
- Suh YJ6
- Kim KS7
- Park WC8
- Yoon CI8
- Lee YJ8
- Kim D8
- Bae SY8
- Korean Breast Cancer Society
- Affiliations
-
- 1Department of Surgery, The Catholic University Graduate School, Seoul, Korea
- 2Division of Breast Surgery, Department of Surgery, Ajou University Medical Center, Ajou University, School of Medicine, Suwon, Korea
- 3Division of Breast Surgery, Department of Surgery, Gangnam Severance Hospital, Yonsei University Medical College, Seoul, Korea
- 4Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 5Division of Breast Surgical Oncology, Department of Surgery, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea
- 6Division of Breast and Thyroid Surgical Oncology, Department of Surgery, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea
- 7Division of Breast Surgery, Department of Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
- 8Division of Breast Surgery, Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- KMID: 2563971
- DOI: http://doi.org/10.4048/jbc.2024.0186
Abstract
- By investigating the characteristics and prognosis of breast cancer (BC) patients who have undergone hormone replacement therapy (HRT), this study addresses a gap in the existing literature. A total of 17,355 postmenopausal patients with BC were analyzed using data from the Korea Breast Cancer Society database (2000–2014). Among them, 3,585 (20.7%) had a history of HRT before BC diagnosis (HRT group), while 13,770 (79.3%) never received HRT (non-HRT group). The HRT group exhibited an earlier pathologic stage, lower histologic and nuclear grades, and a higher rate of breast conservation surgery compared to the non-HRT group. Furthermore, this group had a higher rate of screening participation and a greater proportion of patients with a normal or overweight body mass index (BMI). The prognosis of the HRT group was better than that of the non-HRT group, with a 5-year overall survival rate of 93.9% versus 91.7% (p < 0.001). The hazard ratio for the HRT group was 0.7 (95% confidence interval, 0.608–0.805; p < 0.001). Increased screening participation, longer HRT duration, and a normal or overweight BMI were associated with a better prognosis in the HRT group. Patients with BC who underwent HRT showed better clinicopathological characteristics and prognosis than those who did not receive HRT. The results highlighted significant differences in patients who underwent screening and those with a normal or overweight BMI. Furthermore, a longer HRT duration was associated with a better prognosis.
